flurbiprofen has been researched along with Learning Disabilities in 2 studies
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.
flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.
Learning Disabilities: Conditions characterized by a significant discrepancy between an individual's perceived level of intellect and their ability to acquire new language and other cognitive skills. These may result from organic or psychological conditions. Relatively common subtypes include DYSLEXIA, DYSCALCULIA, and DYSGRAPHIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ibuprofen treatment significantly reduced microglia area in cortex and hippocampus but not beta-amyloid burden." | 1.35 | CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. ( Cenacchi, V; Facchinetti, F; Hutter-Paier, B; Imbimbo, BP; Lanzillotta, A; Pizzi, M; Villetti, G; Volta, R; Windisch, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imbimbo, BP | 1 |
| Hutter-Paier, B | 1 |
| Villetti, G | 1 |
| Facchinetti, F | 1 |
| Cenacchi, V | 1 |
| Volta, R | 1 |
| Lanzillotta, A | 1 |
| Pizzi, M | 1 |
| Windisch, M | 1 |
| Kukar, T | 1 |
| Prescott, S | 1 |
| Eriksen, JL | 1 |
| Holloway, V | 1 |
| Murphy, MP | 1 |
| Koo, EH | 1 |
| Golde, TE | 1 |
| Nicolle, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF 5074 in Healthy Young Male Subjects[NCT00954252] | Phase 1 | 84 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for flurbiprofen and Learning Disabilities
| Article | Year |
|---|---|
CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2009 |
Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cyclooxyge | 2007 |